Characteristics of patients receiving haploidentical transplant between 2013 and 2020 at a US TC, reported to the CIBMTR and with sufficient HLA typing for evaluation
| Characteristic . | |
|---|---|
| Number of patients | 9696 |
| No. of centers | 180 |
| Patient related | |
| Patient age, y | |
| Median (range) | 50 (0-87) |
| Age group, y (by decade), n (%) | |
| 0-9 | 759 (7.8) |
| 10-19 | 900 (9.3) |
| 20-29 | 1077 (11.1) |
| 30-39 | 877 (9) |
| 40-49 | 1114 (11.5) |
| 50-59 | 1845 (19) |
| 60-69 | 2424 (25) |
| 70-79 | 695 (7.2) |
| ≥80 | 5 (0.1) |
| Broad race, n (%) | |
| African American | 1863 (19.2) |
| Asian and Pacific Islander | 532 (5.5) |
| Non-Hispanic White | 5172 (53.3) |
| Hispanic | 1659 (17.1) |
| Multiple race | 172 (1.8) |
| Native American | 41 (0.4) |
| Unknown | 257 (2.7) |
| Sex, n (%) | |
| Male | 5745 (59.3) |
| Female | 3951 (40.7) |
| Donor related | |
| Age, y | |
| Median (range) | 35 (0-77) |
| Age group, y (by decade), n (%) | |
| 0-9 | 72 (0.7) |
| 10-19 | 800 (8.3) |
| 20-29 | 2430 (25.1) |
| 30-39 | 2880 (29.7) |
| 40-49 | 1996 (20.6) |
| 50-59 | 1027 (10.6) |
| 60-69 | 419 (4.3) |
| ≥70 | 31 (0.3) |
| Missing | 41 (0.4) |
| Sex, n (%) | |
| Male | 5746 (59.3) |
| Female | 3949 (40.7) |
| Missing | 1 (0) |
| Disease related | |
| Primary disease, n (%) | |
| Autoimmune disorder | 7 (0.1) |
| Acute lymphoid leukemia | 1608 (16.6) |
| Acute myeloid leukemia | 3694 (38.1) |
| Chronic myeloid leukemia | 289 (3) |
| Hodgkin lymphoma | 256 (2.6) |
| Histiocytic disorders | 52 (0.5) |
| Hemoglobinopathies | 291 (3) |
| Inherited immune disorders | 193 (2) |
| Inherited disorders of metabolism | 30 (0.3) |
| Inherited platelet abnormalities | 2 (0) |
| Inherited bone marrow failure syndromes | 44 (0.5) |
| Myelodysplastic syndromes | 1281 (13.2) |
| Myeloproliferative neoplasms | 281 (2.9) |
| Non-Hodgkin lymphoma | 851 (8.8) |
| Other disease | 11 (0.1) |
| Other acute leukemia | 119 (1.2) |
| Other leukemia | 156 (1.6) |
| Plasma cell disorders | 159 (1.6) |
| Paroxysmal nocturnal hemoglobinuria | 13 (0.1) |
| Severe aplastic anemia | 310 (3.2) |
| Solid tumor | 49 (0.5) |
| Transplantation related | |
| GVHD prophylaxis, n (%) | |
| PTCy | 8400 (86.6) |
| Other | 796 (8.2) |
| Unknown | 500 (5.2) |
| Transplantation year, n (%) | |
| 2013 | 304 (3.1) |
| 2014 | 653 (6.7) |
| 2015 | 944 (9.7) |
| 2016 | 1178 (12.1) |
| 2017 | 1433 (14.8) |
| 2018 | 1582 (16.3) |
| 2019 | 1787 (18.4) |
| 2020 | 1815 (18.7) |
| Characteristic . | |
|---|---|
| Number of patients | 9696 |
| No. of centers | 180 |
| Patient related | |
| Patient age, y | |
| Median (range) | 50 (0-87) |
| Age group, y (by decade), n (%) | |
| 0-9 | 759 (7.8) |
| 10-19 | 900 (9.3) |
| 20-29 | 1077 (11.1) |
| 30-39 | 877 (9) |
| 40-49 | 1114 (11.5) |
| 50-59 | 1845 (19) |
| 60-69 | 2424 (25) |
| 70-79 | 695 (7.2) |
| ≥80 | 5 (0.1) |
| Broad race, n (%) | |
| African American | 1863 (19.2) |
| Asian and Pacific Islander | 532 (5.5) |
| Non-Hispanic White | 5172 (53.3) |
| Hispanic | 1659 (17.1) |
| Multiple race | 172 (1.8) |
| Native American | 41 (0.4) |
| Unknown | 257 (2.7) |
| Sex, n (%) | |
| Male | 5745 (59.3) |
| Female | 3951 (40.7) |
| Donor related | |
| Age, y | |
| Median (range) | 35 (0-77) |
| Age group, y (by decade), n (%) | |
| 0-9 | 72 (0.7) |
| 10-19 | 800 (8.3) |
| 20-29 | 2430 (25.1) |
| 30-39 | 2880 (29.7) |
| 40-49 | 1996 (20.6) |
| 50-59 | 1027 (10.6) |
| 60-69 | 419 (4.3) |
| ≥70 | 31 (0.3) |
| Missing | 41 (0.4) |
| Sex, n (%) | |
| Male | 5746 (59.3) |
| Female | 3949 (40.7) |
| Missing | 1 (0) |
| Disease related | |
| Primary disease, n (%) | |
| Autoimmune disorder | 7 (0.1) |
| Acute lymphoid leukemia | 1608 (16.6) |
| Acute myeloid leukemia | 3694 (38.1) |
| Chronic myeloid leukemia | 289 (3) |
| Hodgkin lymphoma | 256 (2.6) |
| Histiocytic disorders | 52 (0.5) |
| Hemoglobinopathies | 291 (3) |
| Inherited immune disorders | 193 (2) |
| Inherited disorders of metabolism | 30 (0.3) |
| Inherited platelet abnormalities | 2 (0) |
| Inherited bone marrow failure syndromes | 44 (0.5) |
| Myelodysplastic syndromes | 1281 (13.2) |
| Myeloproliferative neoplasms | 281 (2.9) |
| Non-Hodgkin lymphoma | 851 (8.8) |
| Other disease | 11 (0.1) |
| Other acute leukemia | 119 (1.2) |
| Other leukemia | 156 (1.6) |
| Plasma cell disorders | 159 (1.6) |
| Paroxysmal nocturnal hemoglobinuria | 13 (0.1) |
| Severe aplastic anemia | 310 (3.2) |
| Solid tumor | 49 (0.5) |
| Transplantation related | |
| GVHD prophylaxis, n (%) | |
| PTCy | 8400 (86.6) |
| Other | 796 (8.2) |
| Unknown | 500 (5.2) |
| Transplantation year, n (%) | |
| 2013 | 304 (3.1) |
| 2014 | 653 (6.7) |
| 2015 | 944 (9.7) |
| 2016 | 1178 (12.1) |
| 2017 | 1433 (14.8) |
| 2018 | 1582 (16.3) |
| 2019 | 1787 (18.4) |
| 2020 | 1815 (18.7) |
Total number of patients included, N = 9696.